This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Five years ago, in 2016, the W2O Group said that, “Relevance is reputation.” ” That year the firm began to study the relevance of, well, relevance for organizations especially operating in the health/care ecosystem. These ten are all lifescience/pharma companies. The top ten were: AstraZeneca.
. “We” was a trio including Antoinette Thomas (@NurseTechExec1), Chief Patient Experience Officer with Microsoft, David Ryan (@DavidPRyan), former long-time Global Head of Intel’s Health/LifeScience business; and, me. But connectivity became a Super Determinant of health.
Surprising, because technology [and health] underpin virtually all of the fastest-growing brands in 2020, shown in the second chart from Morning Consult’s study of U.S. Interestingly, these are two of the most prominent lifescience companies that have been part of Operation Warp Speed to accelerate the development of COVID-19 vaccines.
This group is less likely to support universal health care or the guarantee of pre-existing condition coverage, yet are more keen on access to treatment for drug and alcohol service. Technology, biotech, hospitals, and lifescience companies would be the health care improvers, most Americans told RealClear pollsters.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content